Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54

Ticagrelor reduced major adverse cardiovascular event (MACE) by 15-16% in patients with prior myocardial infarction (MI) in PEGASUS-TIMI 54. We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular bene...

Full description

Saved in:

Bibliographic Details
Published in:	European heart journal Vol. 37; no. 14; p. 1133
Main Authors:	Bonaca, Marc P, Bhatt, Deepak L, Steg, P Gabriel, Storey, Robert F, Cohen, Marc, Im, Kyungah, Oude Ophuis, Ton, Budaj, Andrej, Goto, Shinya, López-Sendón, José, Diaz, Rafael, Dalby, Anthony, Van de Werf, Frans, Ardissino, Diego, Montalescot, Gilles, Aylward, Philip, Magnani, Giulia, Jensen, Eva C, Held, Peter, Braunwald, Eugene, Sabatine, Marc S
Format:	Journal Article
Language:	English
Published:	England 07.04.2016
Subjects:	Adenosine - administration & dosage Adenosine - adverse effects Adenosine - analogs & derivatives Aged Drug Administration Schedule Female Hemorrhage - chemically induced Humans Male Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - mortality Myocardial Ischemia - mortality Myocardial Ischemia - prevention & control Purinergic P2Y Receptor Antagonists - administration & dosage Purinergic P2Y Receptor Antagonists - adverse effects Risk Factors Secondary Prevention Treatment Outcome Antiplatelet therapy Secondary prevention P2Y12 inhibition Ischaemic risk Platelet inhibition Ticagrelor Coronary artery disease
ISSN:	1522-9645, 1522-9645
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!